Compound designed in New Zealand starves cancer cells of glucose
4 August 2011
Scientists from the Auckland Cancer Society Research Centre (ACSRC) and Maurice Wilkins Centre for Molecular Biodiscovery have designed a new compound that starves certain cancer cells of glucose, depriving them of energy.
New Zealand cancer drug to commence clinical trials
13 June 2011
A novel cancer drug designed by scientists from The University of Auckland and Maurice Wilkins Centre for Molecular Biodiscovery, and licensed to university spin-out company Pathway Therapeutics, Inc., has received approval from the US Food and Drug Administration to enter c...
New Zealand-designed anti-tumour agent to enter clinical development
7 June 2011
A novel anti-tumour agent, CEN-209, created by New Zealand scientists will enter clinical development under two international agreements announced last week.
New class of anticancer ‘stealth’ drug proceeds to clinical development
23 February 2011
The first of an exciting new class of anti-cancer drugs designed in New Zealand will proceed to clinical development in the United States, following the announcement today of a deal between Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo).